{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:23Z","timestamp":1789750283889,"version":"4.0.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T00:00:00Z","timestamp":1557619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of eravacycline, a novel fluorocycline antibiotic from the tetracycline family. Data Sources: A PubMed search was conducted for data between 1946 and March 2019 using MeSH terms eravacycline and TP-434. An internet search was conducted for unpublished clinical research. Study Selection and Data Extraction: The literature search was limited to English-language studies that described clinical efficacy, safety, and pharmacokinetics in humans and animals. Abstracts featuring prepublished data were also evaluated for inclusion. Data Synthesis: Eravacycline has in vitro activity against multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, extended-spectrum \u03b2-lactamase-producing and carbapenem-resistant Enterobacteriaceae, and Acinetobacter. It was approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults following favorable results of 2 phase III trials, IGNITE 1 and IGNITE 4, compared with ertapenem and meropenem, respectively. The most common adverse drug events associated with eravacycline were infusion site reactions (7.7%), nausea (6.5%), vomiting (3.7%), and diarrhea (2.3%). Relevance to Patient Care and Clinical Practice: Eravacycline will likely be most useful for resistant infections when lack of tolerability, resistant phenotypes, or allergies prevent the use of \u03b2-lactams. Conclusions: Eravacycline is a new tetracycline antibiotic with a broad spectrum of activity that has demonstrated efficacy in the treatment of cIAIs. Although it has activity against multidrug-resistant organisms, data are limited for other indications.<\/jats:p>","DOI":"10.1177\/1060028019850173","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T02:11:57Z","timestamp":1557713517000},"page":"1124-1135","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Eravacycline: The Tetracyclines Strike Back"],"prefix":"10.1177","volume":"53","author":[{"given":"Maria","family":"Heaney","sequence":"first","affiliation":[{"name":"Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica V.","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0887","authenticated-orcid":false,"given":"Jason C.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Temple University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,5,12]]},"reference":[{"key":"bibr1-1060028019850173","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Published April 23, 2013. Accessed December 6, 2018."},{"key":"bibr2-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01277-13"},{"key":"bibr3-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"bibr4-1060028019850173","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23061264"},{"key":"bibr5-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1590\/S0103-50532006000800021"},{"key":"bibr6-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.317"},{"key":"bibr7-1060028019850173","doi-asserted-by":"publisher","DOI":"10.2307\/1589259"},{"key":"bibr8-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4690.1190"},{"key":"bibr9-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(55)90593-6"},{"key":"bibr10-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1954.00250030021004"},{"key":"bibr11-1060028019850173","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm224370.htm. Published September 27, 2013. Accessed December 6, 2018."},{"key":"bibr12-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70005-6"},{"key":"bibr13-1060028019850173","unstructured":"Nuzyra [package insert]. Boston, MA: Paratek Pharmaceutical, Inc; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. Accessed December 6, 2018."},{"key":"bibr14-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"bibr15-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"bibr16-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.12.013"},{"key":"bibr17-1060028019850173","unstructured":"Xerava [package insert]. Watertown, MA: Tetraphase Pharmaceuticals, Inc; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf. Accessed November 7, 2018."},{"key":"bibr18-1060028019850173","unstructured":"Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc; 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021821s021lbl.pdf. Accessed December 6, 2018."},{"key":"bibr19-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"bibr20-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.02.014"},{"key":"bibr21-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1021\/jm201465w"},{"key":"bibr22-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-7020-6285-8.00146-5"},{"key":"bibr23-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387"},{"key":"bibr24-1060028019850173","unstructured":"US Food and Drug Administration. Eravacycline\u2014injection products. FDA-identified interpretive criteria. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm618563.htm. Accessed December 6, 2018."},{"key":"bibr25-1060028019850173","unstructured":"Lawrence K, Efimova E, Morrisey I, Hawser S, Fyfe S, Olesky M. Global in vitro activity of eravacycline and comparators against Enterobacteriaceae,\n                      Acinetobacter baumannii, Stenotrophomonas maltophilia, Staphylococcus aureus\n                      , and\n                      Enterococcus\n                      spp, including multidrug-resistant (MDR) isolates from 2016. Poster 630. Poster presented at: ASM Microbe; June 7-11, 2018; Atlanta, GA."},{"key":"bibr26-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2016.73"},{"key":"bibr27-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"bibr28-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02403-15"},{"key":"bibr29-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.022"},{"key":"bibr30-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-018-1349-7"},{"key":"bibr31-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2018.06.016"},{"key":"bibr32-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02206-17"},{"key":"bibr33-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx147"},{"key":"bibr34-1060028019850173","volume-title":"Poster 1832. Poster presented at: IDWeek","author":"Horn P"},{"key":"bibr35-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"bibr36-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"bibr37-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"bibr38-1060028019850173","volume-title":"Poster 264. Poster presented at: ASM Microbe","author":"Tsai L"},{"key":"bibr39-1060028019850173","unstructured":"Decision Resources Group. Tetraphase reports negative results of eravacycline in cUTI trial. https:\/\/decisionresourcesgroup.com\/drg-blog\/tetraphase-reports-negative-results-eravacycline-cuti-trial-2\/. Accessed November 25, 2018."},{"key":"bibr40-1060028019850173","volume-title":"Poster 265. Poster presented at: ASM Microbe","author":"Tsai L"},{"key":"bibr41-1060028019850173","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2016.04.021"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019850173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019850173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019850173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:01Z","timestamp":1777374901000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019850173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,12]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1177\/1060028019850173"],"URL":"https:\/\/doi.org\/10.1177\/1060028019850173","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,12]]}}}